Optimer Pharmaceuticals Announces Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID Phase 3 Data

Optimer Pharmaceuticals, Inc. OPTR today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection. The first analysis aimed to identify risk factors associated with early recurrence (a relapse within the first two weeks after end of therapy) compared to late recurrence (a relapse during the third and fourth weeks after end of therapy). The second poster presented today demonstrates that DIFICID is minimally absorbed with plasma levels in the low ng/mL range while maintaining high fecal concentration that are well in excess of the MIC90 versus C. difficile. The analysis measured the concentration of DIFICID and its metabolite, OP-1118, in the plasma and feces of patients treated with the drug in the Phase 3 clinical studies.